Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Index
-
Market Cap
292.76B
Enterprise Value
318.87B
Income
11.03B
Sales
62.38B
Book/sh
33.36
Cash/sh
5.27
Employees
96100
IPO
Oct 17, 2003
P/E
26.71
Forward P/E
16.63
PEG
1.48
P/S
4.69
P/B
5.66
P/C
35.85
P/FCF
28.46
EV/EBITDA
15.22
EV/Sales
5.11
Quick Ratio
0.79
Current Ratio
1.01
Debt/Eq
0.66
LT Debt/Eq
0.56
Option/Short
Yes / Yes
EPS (ttm)
7.07
EPS next Y
11.35
EPS next Q
2.33
EPS this Y
12.04%
EPS next Y
10.62%
EPS next 5Y
11.24%
EPS past 3/5Y
45.90% 22.05%
Sales past 3/5Y
9.82% 16.31%
EPS Y/Y TTM
17.34%
Sales Y/Y TTM
7.32%
EPS Q/Q
23.13%
Sales Q/Q
6.70%
Insider Own
3.44%
Insider Trans
-0.02%
Inst Own
60.81%
Inst Trans
-0.89%
ROA
9.41%
ROE
22.60%
ROIC
13.70%
Gross Margin
74.11%
Oper. Margin
23.31%
Profit Margin
17.68%
SMA20
9.95%
SMA50
13.67%
SMA200
4.82%
Trades
Shs Outstand
1.55B
Shs Float
1.50B
52W High
212.71 -11.25%
52W Low
153.41 23.05%
Volatility
1.99% 1.88%
ATR (14)
4.45
RSI (14)
73.05
Beta
0.28
Rel Volume
1.47
Avg Volume
3.21M
Volume
3,067,690
Perf Week
8.24%
Perf Month
17.89%
Perf Quarter
16.94%
Perf Half Y
3.42%
Perf YTD
7.56%
Perf Year
14.23%
Perf 3Y
49.46%
Perf 5Y
50.45%
Perf 10Y
249.57%
Prev Close
189.01
Price
188.77
Change %
-0.13%
Consensus
Buy
Avg. Price Target
$228.13
Implied Upside
+20.9%
Analysts3incl. previous ratings
Rating Distribution1 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 15, 2026Upgrade
DB logoDDeutsche Bank
Sell → Hold
Sep 09, 2026Initiated
RY logoRRBC Capital Mkts
Outperform
Jul 13, 2026Downgrade
HSBC logoHHSBC Securities
Buy → Hold
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sharma ManiSee RemarksAug 08 '26Buy160.57203,24919,288Sep 11 04:05 PM
Sharma ManiSee RemarksMay 20 '26Sale185.7811,8932,209,48219,262May 22 04:05 PM
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.
M.B.A.Mr. Pascal Claude Roland Soriot D.V.M.
CFO & Executive DirectorDr. Aradhana Sarin M.D.
EVP of Global opt. & ITMs. Pam P. Cheng
Head of Investor RelationsMr. Joris Silon
CHROMr. Jeffrey Pott J.D.